Simple, Rapid Test May Be Suitable for Newborn or Family Screening
Philadelphia, PA. (March 23, 2010) –A newly developed test appears highly accurate in identifying newborns with fragile X syndrome-the most common inherited cause of cognitive impairment-as well as identifying couples who are carriers of the causative gene, reports a study in the March issue of Genetics in Medicine (www.geneticsinmedicine.org), the official peer-reviewed journal of The American College of Medical Genetics. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.
The new test “overcomes the technical block to institute programs of newborn screening or population-based carrier detection for fragile X syndrome,” according to the study, led by Feras M. Hantash, M.S., Ph.D., of Quest Diagnostics, San Juan Capistrano, Calif.
Quick Test May Overcome Barriers to Fragile X Screening
Fragile X syndrome, which causes intellectual disability and other abnormalities, affects about 1 in 4,000 males in the United States (Fragile X syndrome also occurs in females, but causes less severe impairment). Fragile X syndrome is caused by mutations of a gene called FMR1. The mutations are relatively common in the population-although estimates vary, 1 in 300 to 400 U.S. couples may be carriers of the abnormal genes.
Currently available tests are too expensive and time-consuming for use in routine screening of couples and newborns. As a result, testing is generally done only when there’s some reason to suspect the family is at high risk, such as a previous child with fragile X syndrome.To overcome these obstacles, the researchers developed a new test for mutations of the FMR1 gene. Using polymerase chain reaction (PCR) technology to detect abnormalities called “CGG repeats,” the test detects not only full disease-causing mutations, but also more mild gene expansions called premutations.
In samples with previously identified FMR1 mutations, the new PCR test showed a distinct “stutter” pattern whenever a full or partial mutation was present. It was also capable of detecting FMR1 “mosaics,” which can be difficult to detect with standard approaches. The test was further evaluated in a series of 1,275 blood samples submitted for fragile X testing. The results showed a 100 percent rate of agreement between the new test and the standard “Southern blot” test. Mutations were found in 6 of the 1,275 patients tested.
With further study, the new PCR test may open the way to more widespread testing for fragile X mutations. This could include routine screening of newborns, as the test can detect FMR1 mutations in standard newborn blood spots. Abnormal screening results would require further diagnostic evaluation, including the standard Southern blot test. The researchers estimate that the screening test could reduce the number of Southern blot tests performed by 99 percent, thus saving considerable time and money.
More research will be needed before the ACMG and other organizations issue official recommendations on prenatal screening. In addition to medical and scientific questions, studies will need to address the ethical and legal issues involved with screening for fragile X syndrome. “It certainly will be a challenge to educate the public about the complexities of fragile X testing,” Dr. Hantash and colleagues write.
Note to editors: Interviews with the lead authors available upon request by contacting Kathy Beal, Public Relations Director for the ACMG: phone 301-238-4582 or e-mail kbeal@acmg.net
About Genetics in Medicine
Genetics in Medicine (geneticsinmedicine.org) is the official peer-reviewed journal of The American College of Medical Genetics. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
About the American College of Medical Genetics
Founded in 1991, the ACMG (www.acmg.net) provides education, resources and a voice for the medical genetics profession. To make genetic services available to and improve the health of the public, the ACMG promotes the development and implementation of methods to diagnose, treat and prevent genetic disease. Members include biochemical, clinical, cytogenetic, medical and molecular geneticists, genetic counselors, and other health care professionals committed to the practice of medical genetics. Genetics in Medicine, published monthly, is the official journal of the ACMG.
Lippincott Williams & Wilkins
Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services.
LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons®; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span® and ProVation® Medical.
Wolters Kluwer Health is part of Wolters Kluwer, a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2009 annual revenues of €3.4 billion ($4.8 billion), employs approximately 18,200 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Visit www.wolterskluwer.com for information about our market positions, customers, brands, and organization.
Contacts:
Robert Dekker
Director of Communications
Wolters Kluwer Health
215-521-8928
Robert.Dekker@wolterskluwer.com
Carole Bernstein
Marketing Manager
Lippincott Williams and Wilkins
215-521-8300
Carole.Bernstein@wolterskluwer.com